On 02 March 2015 we have announced that our major three-part transaction with Novartis has completed.
As a result, GSK has acquired Novartisís global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and divested our marketed Oncology business to Novartis.
Completion of this transaction represents a major step forward in the Groupís strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines."
Previously published documents regarding the transaction are below:
- Read the GSK/Novartis transaction press release issued 02 March 2015